You make some good points. Only the highly visible, widely followed biotechs are acting well right now. EBIO is in neither group. Their niche is a good one, though, and they should become recognized for the company they keep...Applied Biosystems. Second deal was with Third Wave. Company is about to complete a third deal shortly.
They said the manufacturing acquisition would take 2001 revenues up from just under $4 million to $11 million with a loss of about 11 cents per share. Auerbach was showing a loss of 9 cents in 2001 on $3.8 million revenues.
The key is, how quickly they can accelerate demand for their probes. At some point between $11 to $20 million in volume, they will clearly go profitable if they control costs. The markets they serve are and will continue to grow very quickly (+30%/yr.) according to most forecasts.
$5 share purchases this week might look very good a few months out from now. Also, recent favorable mention about Epoch in NYTimes Biotech article where a fund manager was buying it recently as it was at attractive pricing below $8 or so.
Appreciate any additional information you can provide. Thanks